‘When it comes to developing medicines available for all populations in the world, the image of Big Pharma has long been tarnished. Supply bottlenecks for some specific drugs are often the result of the pricing policies pursued by major drugmakers, says Wasem [Jürgen Wasem, a professor for healthcare management at the University of Duisburg-Essen in Germany] — a claim, which is nonetheless "difficult to prove in most cases," he says. Sometimes, companies strive to keep supply artificially low, he says, to achieve higher market prices. Moreover, certain treatments are often never developed because there isn't a "commercial incentive" to undertake the effort, he adds.’
Read here (DW, May 1, 2020)
